5 completed, 3 terminated, 1 active not recruiting. 8 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Terminated 2, Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Mersana Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) Upifitimab rilsodotin, Placebo - High Grade Serous Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Terminated | Mersana Therapeutics | 20 | 2022-06-23 | 2023-10-26 |
| Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer XMT-1536 (Upifitamab Rilsodotin), Carboplatin - Platinum-sensitive Ovarian Cancer (UPGRADE-A) | Phase 1 | Terminated | Mersana Therapeutics | 31 | 2021-06-11 | 2023-10-10 |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b XMT-1592 - Ovarian Cancer, Nonsmall Cell Lung Cancer | Phase 1 | Terminated | Mersana Therapeutics | 31 | 2020-05-11 | 2024-03-15 |
| First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b upifitamab rilsodotin - Platinum Resistant Ovarian Cancer, Non-Small Cell Adenocarcinoma | Phase 1 | Completed | Mersana Therapeutics | 142 | 2019-07-30 | 2024-07-24 |
| First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b upifitamab rilsodotin - Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | Phase 1 / Phase 2 | Active not recruiting | Mersana Therapeutics | 523 | 2017-12-12 | 2023-11-13 |
| First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b upifitamab rilsodotin - Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic | Phase 1 | Completed | Mersana Therapeutics | 62 | 2017-12-12 | 2024-07-24 |
| Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 XMT-1522 - Advanced Breast Cancer, Advanced Nonsmall Cell Lung Cancer | Phase 1 | Completed | Mersana Therapeutics | 120 | 2016-11-21 | 2021-02-24 |
| A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors XMT-1001 - Small Cell Lung Cancer, Non-small Cell Lung Cancer | Phase 1 | Completed | Mersana Therapeutics | 30 | 2011-03-01 | 2018-01-31 |
| A Study of Intravenous XMT-1107 in Patients With Advanced Solid Tumors XMT-1107 - Neoplasm Metastasis | Phase 1 | Completed | Mersana Therapeutics | 52 | 2010-03-01 | 2018-01-31 |
Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
Carboplatin (1) · XMT 1001 (1) · XMT-1522 (1)
United States (9) · Australia (1) · Canada (1)
Robert Burger, MD (5) · Edward Sausville, MD (2) · Allen Lee Cohn, MD (1) · Brad Sumrow, MD (1) · David A. Smith, MD (1) · Donald A. Richards, MD (1) · Eric P. Hailman, MD, PhD (1) · Fadi Braiteh, MD (1) · Geoffrey Shapiro, MD (1) · Glen J Weiss, MD (1) · Hillary H. Wu, MD (1) · Johana Bendell, MD (1) · John R. Caton, MD (1) · Lawrence Garbo, MD (1) · Paul R. Conkling, MD (1)